Literature DB >> 9459313

Association of a common polymorphism in the factor XIII gene with myocardial infarction.

H P Kohler1, M H Stickland, N Ossei-Gerning, A Carter, H Mikkola, P J Grant.   

Abstract

Factor XIII when activated by thrombin, crosslinks fibrin, however its role in thrombotic disorders is unknown. A common point mutation (G-->T) in exon 2 of the A-subunit gene which codes for an amino acid change three amino acids from the thrombin activation site (Factor XIIIVal34Leu) is a candidate for a role in the pathogenesis of acute myocardial infarction. Factor XIII genotype frequencies were determined in a case-control study of 398 caucasian patients and 196 healthy controls. Patients had undergone angiography for investigation of coronary artery disease and were evaluated for a history of myocardial infarction. The prevalence of the mutation was lower in patients with myocardial infarction than without (32% vs. 50%), p = 0.0009 and than in controls (32% vs. 48%), p = 0.005. Patients possessing the mutation with a history of myocardial infarction had higher PAI-1 concentrations (mean, 27.9 vs. 16.7 ng/ml, p = 0.004) and the PAI-1 4G/4G genotype was commoner (43% vs. 26%, p = 0.03). There was no difference in PAI-1 4G/4G genotype (33% vs. 32%) and PAI-1 levels (mean, 21.0 vs. 20.9 ng/ml) in patients possessing wild type with MI compared to those without MI. These results indicate that the G-->T mutation coding for factor XIIIVal34Leu is protective against myocardial infarction and suggest a mechanism whereby elevated levels of PAI-1 may contribute to vascular risk.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9459313

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  28 in total

Review 1.  Candidate genes and confirmed genetic polymorphisms associated with cardiovascular diseases: a tabular assessment.

Authors:  Z Tang; R P Tracy
Journal:  J Thromb Thrombolysis       Date:  2001-02       Impact factor: 2.300

2.  The impact of factor XIIIa V34L polymorphism on plasma factor XIII activity in the Chinese and Asian Indians from Singapore.

Authors:  Chew-Kiat Heng; Suman Lal; Nilmani Saha; Poh-Sim Low; M Ilyas Kamboh
Journal:  Hum Genet       Date:  2003-10-31       Impact factor: 4.132

3.  Factor XIII Val34Leu polymorphism and gamma-chain cross-linking at the site of microvascular injury in healthy and coumadin-treated subjects.

Authors:  A Undas; B Brzezinska-Kolarz; K Brummel-Ziedins; J Musial; A Szczeklik; K G Mann
Journal:  J Thromb Haemost       Date:  2005-09       Impact factor: 5.824

4.  Impact of FXIII-A Val34Leu polymorphism on coronary artery disease in Croatian patients.

Authors:  Ana Bronić; Goran Ferencak; Renata Zadro; Ana Stavljenić-Rukavina; Robert Bernat
Journal:  Mol Biol Rep       Date:  2007-09-27       Impact factor: 2.316

5.  PAI-1 4G/5G polymorphism and coronary artery disease risk: a meta-analysis.

Authors:  Zhongshu Liang; Weihong Jiang; Mao Ouyang; Kan Yang
Journal:  Int J Clin Exp Med       Date:  2015-02-15

Review 6.  Newly-Recognized Roles of Factor XIII in Thrombosis.

Authors:  James R Byrnes; Alisa S Wolberg
Journal:  Semin Thromb Hemost       Date:  2016-04-07       Impact factor: 4.180

Review 7.  Thrombophilia, polymorphisms, and vascular disease.

Authors:  T C Sykes; C Fegan; D Mosquera
Journal:  Mol Pathol       Date:  2000-12

8.  Design of Factor XIII V34X activation peptides to control ability to interact with thrombin mutants.

Authors:  Madhavi A Jadhav; R Cory Lucas; Whitney N Goldsberry; Muriel C Maurer
Journal:  Biochim Biophys Acta       Date:  2011-07-21

9.  Molecular genetics of myocardial infarction.

Authors:  Yoshiji Yamada; Sahoko Ichihara; Tamotsu Nishida
Journal:  Genomic Med       Date:  2008-08-14

Review 10.  Clinical significance of gene-diagnosis for defects in coagulation factors and inhibitors.

Authors:  Herbert H Watzke
Journal:  Wien Klin Wochenschr       Date:  2003-08-14       Impact factor: 1.704

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.